[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Healthcare Market Research Reports & Industry Analysis

Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.

Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.

The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.

Publications found: 112,550
Sort by:

Global Dermatology Market 2013-2023

US$ 3,000.00

... from 2013-2023. The report will be valuable to those already involved in the dermatology market or to those wishing to enter this important market in the future. The Global Dermatology Market 2013-2023 report ...

September 2013 170 pages

Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1,2, STELARA, GSK-1605786, Vercirnon, Traficet-EN

US$ 250.00

Takeda received priority review status from US FDA for its late stage candidate Vedolizumab (filed for UC and Crhon’s disease (CD), a4ß7 integrin inhibitor) to treat ulcerative colitis indication. Vedolizumab targets the disease by preventing ...

September 2013 7 pages

Ear Care in the Netherlands

US$ 990.00

Sales of ear care registered marginally improved current value growth of 6% in 2012 compared to 5% growth in the previous year. Increased demand for ear care is attributed to promotional efforts from main manufacturers aimed at making consumers aware of the benefits of maintaining good ear health. Euromonitor International's Ear Care in Netherlands ...

September 2013 23 pages

Chefaro International BV in Consumer Health (Netherlands)

US$ 150.00

Chefaro International, which has changed its name to Omega Pharma Nederland, moved its production in 2012 from Rotterdam to a sister company in Feldkirchen, ... distribution data. Why buy this report? Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors driving ...

September 2013 2 pages

Maxim Sportvoeding Benelux in Consumer Health (Netherlands)

US$ 150.00

Maxim Sportvoeding Benelux is still a relatively small manufacturer within Dutch consumer health. The player is aiming to increase its position in the Netherlands by ... data. Why buy this report? Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors driving ...

September 2013 2 pages

Optimax BV in Consumer Health (Netherlands)

US$ 150.00

... . Product coverage: Allergy Care, Herbal/Traditional Products, OTC, Paediatric Consumer Health, Sports Nutrition, Vitamins and Dietary Supplements, Weight Management. ... data. Why buy this report? Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors driving ...

September 2013 2 pages

Springfield Nutraceuticals in Consumer Health (Netherlands)

US$ 150.00

... are likely to affect more Dutch consumers over the coming years such as eye health, prostate cancer and menopause. Springfield is focusing on increasing its ... distribution data. Why buy this report? Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors driving ...

September 2013 2 pages

Ecoproduct PK in Health and Wellness (Ukraine)

US$ 150.00

The strategy of Ecoproduct is to focus on further expansion to become the leading niche player in health and wellness tea (fruit/herbal and medicinal) ... and distribution data. Why buy this report? Get a detailed picture of the Health and Wellness market; Pinpoint growth sectors and identify factors driving ...

September 2013 2 pages

Gimel AD in Health and Wellness (Bulgaria)

US$ 150.00

The company is among the leading producers of greenhouse cucumbers and tomatoes in Bulgaria. It is a main supplier of organic greenhouse vegetables in Europe and it covers the ... data. Why buy this report? Get a detailed picture of the Health and Wellness market; Pinpoint growth sectors and identify factors ...

September 2013 2 pages

Internet Café BG EOOD in Health and Wellness (Bulgaria)

US$ 150.00

The company operates Zoya.bg organic shops, consisting of an online store which delivers nationwide and a brick-and-mortar outlet in the capital Sofia. Zoya.bg aims to work only with certified bio food manufacturers and traders. Its outlets offer a wide range of packaged and unpackaged food, cosmetics and ...

September 2013 2 pages

Lustdorf TOV in Health and Wellness (Ukraine)

US$ 150.00

Lustdorf TOV is a fast-growing and aggressive domestic dairy company in Ukraine. It has ambitious plans to become the leader in premium long-life/UHT ... and distribution data. Why buy this report? Get a detailed picture of the Health and Wellness market; Pinpoint growth sectors and identify factors driving ...

September 2013 2 pages

Food Intolerance in Ukraine

US$ 900.00

... are not well-known among local consumers. Nonetheless, the most significant development in food intolerance has come from gluten-free ... is more widely recognised as small babies often... Euromonitor International's Food Intolerance in Ukraine report tracks the developments of health-associated product types ...

September 2013 20 pages

Consensus Outlook: Multiple Sclerosis

US$ 7,495.00

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $14.4 billion in 2012 to $18.3 billion in 2017. Primary ... efficacious therapy, and continued uptake of existing therapies. Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and ...

August 2013 35 pages

US Proton Therapy Outlook 2017

US$ 2,000.00

... to make it more accessible to patients. According to the “US Proton Therapy Outlook 2017” by RNCOS, the United States will be home to almost 27 such centers ... will breach the Billion dollar mark to attain revenue of US$ 1.17 Billion by 2017. The following 65 pages report provides an insight into the cancer ...

August 2013 65 pages

Physician Views – Sanofi's no-go decision on lixisenatide monotherapy sharpens focus on GLP-1/insulin combination products – what are the expectations of GPs, endocrinologists based in the US, 5EU?

US$ 695.00

... of a combination Lantus/lixisenatide product, but commercial opportunity significant. Sanofi has previously demonstrated a willingness to shift its development strategy ... of Lantus in the long-acting insulin market. This week's Physician Views poll will ask endocrinologists and general practioners based in ...

August 2013

AvroMed LLC in Consumer Health (Azerbaijan)

US$ 150.00

AvroMed LLC is expected to focus on further expanding its range during the forecast period. The company is keen to encourage sales growth for affordable consumer health products and is thus likely to emphasise its own range in its AvroMed chain of pharmaceutical stores during the forecast ...

August 2013 2 pages

Riyad Pharm MMC in Consumer Health (Azerbaijan)

US$ 150.00

Riyad Pharm MMC will continue to benefit from further expansion during the forecast period. It is expected to focus on further expanding its network of ... distribution data. Why buy this report? Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors driving change ...

August 2013 2 pages

Zafaran Apteki MMC in Consumer Health (Azerbaijan)

US$ 150.00

... -competitive products. Zafaran Aptek will work to maintain its leadership in health and beauty specialist retailers by expanding its network of outlets across Azerbaijan. ... data. Why buy this report? Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors driving ...

August 2013 2 pages

Ear Care in South Africa

US$ 990.00

... within ear care. Consumers use such products to try and get rid of excess wax in ears. Products such as Waxsol from Meda AB (represented in South Africa by Norgine ... as Swimmer’s Ear tend to perform well during the summertime when temperatures are higher and people frequently swim. Euromonitor International's Ear Care in South Africa report ...

August 2013 23 pages

Adcock Ingram Healthcare Pty Ltd in Consumer Health (South Africa)

US$ 150.00

... , generic and OTC), but the company also supplies hospital equipment and diagnostic products and services. Adcock Ingram’s vision is to be recognised as a leading world-class branded healthcare company – which it plans to achieve through organic growth and prudent acquisition. It plans to pursue expansion ...

August 2013 3 pages

Cipla-Medpro (Pty) Ltd in Consumer Health (South Africa)

US$ 150.00

Cipla-Medpro focuses on generic medicines. Its vision is to become “the biggest and most admired pharmaceutical company in South Africa”. This vision is ... and distribution data. Why buy this report? Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors driving ...

August 2013 3 pages

Florina Bulgaria AD in Health and Wellness (Bulgaria)

US$ 150.00

Florina Bulgaria is a leading Bulgarian producer of fruit juices. Over the review period, the company pursued rather slow expansion, with only popular ... and distribution data. Why buy this report? Get a detailed picture of the Health and Wellness market; Pinpoint growth sectors and identify factors driving ...

August 2013 2 pages

Food Intolerance in Bulgaria

US$ 900.00

... food. Not only people who are gluten or lactose intolerant purchase such products. Gluten- and lactose-free products are more widely consumed as healthy and weight management options. Euromonitor International's Food Intolerance in Bulgaria report tracks the developments of health-associated product types ...

August 2013 21 pages

Global Medical Publishing 2013-2014

US$ 2,500.00

... books, journals, online content or newsletters, you can trust Global Medical Publishing 2013-2014 to provide the inside intelligence you need to evaluate ... include: The demand for full-text resources The transition of e-publishing Library cost pressures The outlook for pharmaceutical advertising Impact ...

August 2013 70 pages

IPCA - We reiterate our market perform rating for IPCA and increase price target to Rs.740 by valuing the company at 18x of FY15 earnings. We expect revenue and earnings to grow by 16 -17% in next two

US$ 140.00

We reiterate our market perform rating for IPCA and increase price target to Rs.740 by valuing the company at 18x of ...

August 2013 5 pages

RANBAXY - Stretched Balance Sheet, a Weak Product Pipeline, and Uncertainty around Monetizing Exclusivities

US$ 140.00

Q2 CY-13 Result in Line: Sales grew by 8% QoQ primarily on account of higher Absorica (Isotretinoin) sales in US. US sales grew by 29% sequentially as company now has 14% share in Isotretinion (~$400m market). Excluding US, revenue across the geographies remained muted and grew by 1% sequentially and 2% yoy. ...

August 2013 6 pages

SHIONOGI - Tivicay (Dolutegravir) US Approval Comes with an Encouraging Broad Label. Focus Shifts on Data from FLEMINGO Study and Approval of Trii FDC!

US$ 300.00

Tivicay (Dolutegravir) US Approval Comes with an Encouraging Broad Label. Focus Shifts on Data ... Study and Approval of Trii FDC! ViiVhealthcare today announced US approval of Tivicay (Dolutegravir) - it is approved both for treatment naïve and treatment experienced HIV patients ...

August 2013 3 pages

Ear Care in Morocco

US$ 990.00

... ears. Many Moroccans have a habit of using cotton buds daily to clean their ear canals and ear hygiene is deeply rooted locally. Euromonitor International's Ear Care in Morocco ... data. Why buy this report? Get a detailed picture of the Ear Care market; Pinpoint growth sectors and identify factors driving change ...

August 2013 24 pages

CADILA HEALTHCARE, We reiterate our outperform rating on Cadila; however, revise our price target down to Rs.950 (20x of FY15 earnings), owing to the delay in the approval of ANDA’s.

US$ 140.00

We reiterate our outperform rating on Cadila; however, revise our price target down to Rs.950 (20x of FY15 earnings), owing to the delay in the approval of ANDA’s. We lower our revenue ...

August 2013 10 pages

CIPLA , We reiterate our market perform rating on Cipla with a price target of Rs.415 (20x FY-15 earnings) as we expect

US$ 140.00

We reiterate our market perform rating on Cipla with a price target of Rs.415 (20x FY-15 earnings) as we expect 1) Sales growth to ...

August 2013 5 pages

NOVARTIS - String of Pearls- LDK378, Serelaxin followed by breakthrough designation for BYM338 (bimagrumab)

US$ 90.00

Novartis received break through designation from FDA for its third ...

August 2013 2 pages

Ear Care in Portugal

US$ 990.00

... only five to 10 products available in OTC, most being prescription-based. Ear care continued to be hindered by a small product range with Otoceril being the ... product development towards the end of the review period. Ear care... Euromonitor International's Ear Care in Portugal report offers a comprehensive guide to the size and shape ...

August 2013 21 pages

Distrifa- Soluções de Saude Lda in Consumer Health (Portugal)

US$ 150.00

Distrifa - Solucoes de Saude is expected to maintain its current marketing strategy, investing mainly in its Arkocapsulas brand, using product innovation and advertising to boost its sales. Over the forecast period the company is expected to continue to launch calming and sleeping products and dietary ...

August 2013 3 pages

Laboratorio J Neves, Lda in Consumer Health (Portugal)

US$ 150.00

... The company managed to grow with the acquisition of several brands and companies in Portugal and abroad. Laboratorios J.Neves aim is to be among the first pharmaceutical companies in Portugal, but want to grow also by being present in more dynamic markets such as Brazil and Africa, where ...

August 2013 2 pages

Löfbergs Lila AB in Health and Wellness (Sweden)

US$ 150.00

Over the forecast period, Lofbergs Lila will continue to launch new health-oriented tea and coffee products in Sweden, while also working to strengthen the distribution and promotion of its established health and wellness ranges. In particular, the company is expected to focus on expanding its ...

August 2013 2 pages

Rootfruit Scandinavia AB in Health and Wellness (Sweden)

US$ 150.00

Over the forecast period, Rootfruit will work to strengthen its position in organic sweet and savoury snacks by developing new products and stepping ... and distribution data. Why buy this report? Get a detailed picture of the Health and Wellness market; Pinpoint growth sectors and identify factors driving ...

August 2013 2 pages

Food Intolerance in Sweden

US$ 900.00

... number of immigrants of Asian, Middle Eastern and African origin. Additionally, it is likely that many people who... Euromonitor International's Food Intolerance in Sweden report tracks the developments of health-associated product types and the healthy-option positioning of competing brands across different ...

August 2013 30 pages

Ear Care in Iran

US$ 990.00

... glycerin 6.4% is currently the only OTC ear care product officially available in Iran. These products were introduced into Iran during 2006 and have recorded ... in 2012 as the number of elderly people in Iran who require this product is growing rapidly. Euromonitor International's Ear Care in Iran report offers a comprehensive guide to the ...

August 2013 17 pages

Eye Care in Iran

US$ 990.00

... /pharmacies in Iran offer a range of Rx eye care products under-the-counter to customers without a prescription, most Iranian consumers are very wary of using eye care products without first obtaining the advice and guidance of a doctor. Euromonitor International's Eye Care in Iran report offers a comprehensive ...

August 2013 17 pages

Regional Overview: Health and Wellbeing Trends in Latin America

US$ 2,000.00

... growth for the industry in years to come. Euromonitor International’s Regional Overview: Health and Wellbeing Trends in Latin America global briefing examines the size, growth trends and potential opportunities in the Consumer Health market.  The strategic analyses include assessing the impacts of changing ...

August 2013 46 pages

The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry

US$ 1,500.00

... RECENT IVD CONSOLIDATION THE ROLE OF ACOS IMPACT OF THE MEDICAL DEVICE TAX AND RECENT DEVELOPMENTS STATE EXPANSION OF MEDICAID IVD CAPITAL PURCHASING, PUBLIC ... plans offered at that level. Different aspects of the complex health care reform legislation will affect the IVD industry differently, with some ...

August 2013 68 pages

Ear Care in Germany

US$ 990.00

... Germany in 2012, retail value sales of ear care increased by 3% to almost €27 million, making it still one of the smallest niche categories of the OTC market in Germany. According ... for ear wax removal) or went to a doctor when they had a problem which seemed more serious (for example... Euromonitor International's Ear Care in Germany report ...

August 2013 22 pages

Ear Care in Belgium

US$ 990.00

Ear care products are considered non-essential, with sales dominated by products to remove ear wax. It is often subject to irregular developments, depending on the competition ... wool buds, advertising campaigns or rare product launches. Euromonitor International's Ear Care in Belgium report offers a comprehensive guide to the size and shape of the ...

August 2013 30 pages

Ear Care in Austria

US$ 990.00

Ear care saw very good performance in 2012, benefiting from the growing number of health-conscious Austrians. Consumers in Austria pay a great deal of attention ... brands which provide great efficacy was noticeable within ear care in Austria in 2012. Euromonitor International's Ear Care in Austria report offers a comprehensive guide to the size and ...

August 2013 22 pages

Ear Care in Switzerland

US$ 990.00

... of ear care in 2012 and during the review period can be attributed to the low demand for such OTC products. Swiss consumers with ear ache or other ear problems would rather seek a doctor’s advice than try self-medication. When it comes to ear... Euromonitor International's Ear Care in Switzerland report ...

August 2013 25 pages

Austroplant Arzneimittel GmbH in Consumer Health (Austria)

US$ 150.00

Austroplant Arzneimittel focuses on putting people and nature in the spotlight, using only natural ingredients in the production process, thus further strengthening its ... data. Why buy this report? Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors driving ...

August 2013 2 pages

Biomed AG in Consumer Health (Switzerland)

US$ 150.00

... . Product coverage: Allergy Care, Herbal/Traditional Products, OTC, Paediatric Consumer Health, Sports Nutrition, Vitamins and Dietary Supplements, Weight Management. ... data. Why buy this report? Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors driving ...

August 2013 2 pages

Dr A & L Schmidgall KG in Consumer Health (Austria)

US$ 150.00

Dr A & L Schmidgall follows a multi-brand strategy covering a wide consumer base. Over the forecast period the company plans to invest further in the development of its brands in order to establish itself more firmly in all European markets. It intends to achieve this by focusing on delivering the best ...

August 2013 2 pages

Firma Magister Martin Doskar Pharm Produkte eu in Consumer Health (Austria)

US$ 150.00

The main goal of Firma Magister Martin Doskar Pharm Produkte over the forecast period is to establish itself more firmly in the Austrian market, and to continue to offer innovative herbal/traditional products to consumers. In addition, the company is expected to ...

August 2013 3 pages

GlaxoSmithKline GmbH & Co KG in Consumer Health (Germany)

US$ 150.00

Being a (comparatively small) part of a multinational, GlaxoSmithKline GmbH & Co KG as a German subsidiary is involved in research and development work in its three core product divisions: prescription medication, vaccination and consumer health. Its main focus in consumer health in Germany, however, due to ...

August 2013 3 pages

Filters

Search

Categories

370
94
242
550
1,143
110,057
94

Publishers

179
1
100
32
25
102
94
2,211
109
23
40
8,299
68
562
988
34
29,954
248
501
3,036
1
1
2
3
1
16
257
537
361
106
1
1,357
2,180
60
1,696
8
8,921
1,697
4
3,714
983
19
1
321
4,852
2,748
66
1
3
3
36
202
2,355
246
53
50
45
46
29
29
143
56
42
83
9
20
29
5
11
3
16,308
3
270
11
3
292
22
4
39
1
2
6,125
14
1
183
49
359
30
33
4,348
13
1
44
2
7
10
9
12
18
21
168
52
8
3
18
16
7
1
18
1
41
58
350
1
4
6
1
3
9
1
3
5
1
1
1
90
2
3
4
1
77
15
980
1
3
1
17
227
128
16
4
412
3
74
2
6
5
10
1
3
118
33
336
196
47
474
7
45
1
22
13
138
2
4

Regions

58
48
35
31
30
29
29
26
26
23
22
22
22
21
16
15
14
6
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
36
57
41
54
60
101
26
30
55
3
34
2
2
1,179
115
172
26
33
94
14
49
53
28
18
62
25
23
39
23
43
24
14
51
28
38
132
48
65
67
204
52
17
56
42
31
48
47
37
36
19
62
150
34
31
30
17
17
16
14
136
57
49
30
15
457
1,819
71
1,614
921
765
184
2,008
99,858

Price

Date

Pages

Offers

93
23
905
1
2,735
269
1
1